Federal Circuit Rejects Novartis’ Bid To Issue Mandate In Drug Patent Row

( January 15, 2025, 9:38 AM EST) -- WASHINGTON, D.C. — A panel in the Federal Circuit U.S. Court of Appeals on Jan. 14 denied Novartis Pharmaceuticals Corp.’s motion to expedite the issuance of its mandate after finding only a few days earlier that a district judge was right to reject arguments that a Novartis heart failure drug patent was invalid as obvious but wrong to hold that the claims were invalid for lack of written description....

Attached Documents

Related Sections